FDA 483 - Siegfried El Masnou, S.A. - July 11, 2025

The FDA conducted an inspection of Siegfried El Masnou, S.A., a sterile drug product manufacturer located in El Masnou, Barcelona, Spain, from July 1 to July 11, 2025. The inspection revealed significant issues concerning the validation of aseptic processes, crucial for preventing microbiological contamination in sterile drug products.

Key violations included inadequacies in the design and documentation of Media Fill studies, which are essential for simulating aseptic manufacturing conditions. Specifically, the studies failed to document all interventions during the aseptic process, such as the removal of trapped bottles and extraction of fallen tubes, which were observed to occur multiple times during routine operations. Furthermore, the media fill program did not ensure that all interventions, particularly those exceeding qualified limits, were included in subsequent media fills, potentially compromising the representativeness of the process.

Additionally, the Aseptic Process Simulation for certain drug formulations did not adequately reflect commercial manufacturing conditions. For instance, the bulk media was not incorporated into the filling process as it should be, and there was no scientific justification for the selected growth medium or incubation procedures.

The FDA requires Siegfried El Masnou, S.A. to address these deficiencies by ensuring comprehensive documentation and validation of aseptic processes. The company must implement corrective actions to align its operations with regulatory standards, ensuring the sterility and safety of its drug products for the market.